Financial reports
10-Q
2024 Q3
Quarterly report
14 Feb 24
10-Q
2024 Q2
Quarterly report
14 Nov 23
10-Q
2024 Q1
Quarterly report
14 Aug 23
10-K/A
2023 FY
Annual report (amended)
31 Jul 23
10-K
2023 FY
Annual report
29 Jun 23
10-Q
2023 Q3
Quarterly report
14 Feb 23
10-Q
2023 Q2
Quarterly report
14 Nov 22
10-Q
2023 Q1
Quarterly report
15 Aug 22
10-K
2022 FY
Annual report
29 Jun 22
10-Q
2022 Q3
Quarterly report
14 Feb 22
Current reports
8-K
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024
14 Feb 24
8-K
Regulation FD Disclosure
26 Dec 23
8-K
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR® to Marketing Partner Prasco, LLC
12 Dec 23
8-K
Results of Operations and Financial Condition
14 Nov 23
8-K
Regulation FD Disclosure
25 Sep 23
8-K
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
7 Sep 23
8-K
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024
14 Aug 23
8-K
Changes in Registrant's Certifying Accountant
17 Jul 23
8-K
Results of Operations and Financial Condition
29 Jun 23
8-K
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
3 May 23
Registration and prospectus
S-8
Registration of securities for employees
28 Mar 24
S-8
Registration of securities for employees
28 Mar 24
424B3
Prospectus supplement
27 Jul 20
S-3
Shelf registration
15 Jul 20
D
$26M in equity, sold $500K, 1 investor
13 Jul 20
424B3
Prospectus supplement
5 Jun 17
S-3/A
Shelf registration (amended)
2 Jun 17
S-3
Shelf registration
10 May 17
D
$41.6M in equity, sold $800K, 1 investor
10 May 17
424B3
Prospectus supplement
9 Feb 17
Proxies
DEFA14A
Additional proxy soliciting materials
11 May 20
DEF 14A
Definitive proxy
29 Apr 20
PRE 14A
Preliminary proxy
17 Apr 20
DEFA14A
Additional proxy soliciting materials
18 Oct 19
DEF 14A
Definitive proxy
10 Oct 19
PRE 14A
Preliminary proxy
27 Sep 19
DEFA14A
Additional proxy soliciting materials
5 May 14
DEF 14A
Definitive proxy
3 Apr 14
PRE 14A
Preliminary proxy
18 Mar 14
DEF 14A
Definitive proxy
31 Aug 11
Other
UPLOAD
Letter from SEC
12 Mar 21
CORRESP
Correspondence with SEC
22 Feb 21
UPLOAD
Letter from SEC
9 Feb 21
EFFECT
Notice of effectiveness
28 Jul 20
CORRESP
Correspondence with SEC
23 Jul 20
UPLOAD
Letter from SEC
22 Jul 20
CT ORDER
Confidential treatment order
6 Sep 18
CT ORDER
Confidential treatment order
19 Jul 18
CT ORDER
Confidential treatment order
11 Oct 17
CT ORDER
Confidential treatment order
12 Jul 17